Incyte
Prix: 108.53Entreprise et modèle économique
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for oncology and other serious diseases. Its core products include Jakafi, a treatment for certain blood disorders, and other investigational therapies targeting various cancers. The company generates revenue mainly from product sales and collaborations with other pharmaceutical firms.
Profil d’investissement
The investment profile of Incyte is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue increases. However, the current market conditions and performance metrics suggest a cautious approach. The stock may appeal to those with a medium to long investment horizon, prioritizing potential capital appreciation over immediate income. Liquidity is moderate, suitable for investors with basic to advanced experience.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 7.30 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -15.5% ↓
- Surprise BPA
- 31.2% meilleur que prévu
- Volatilité 20 j
- 2.1% stable
Impact de la prévision
positifSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-05 02:40 | Vendre | Acheter | Mixed signals; revenue decline raises caution. |
| 2026-06-03 02:43 | Conserver | Vendre | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-24 02:42 | Vendre | Conserver | Weak fundamentals and mixed momentum signal caution. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-10 11:11 | H.C. Wainwright | Objectif relevé | — → 140 | 103.23 |
| 2026-06-09 13:11 | Stifel Nicolaus | Mettre à jour | — → 123 | 103.07 |
| 2026-06-08 18:53 | Oppenheimer | Objectif relevé | 90 → 107 | 100.64 |
Rien pour le moment